Atazanavir (n = 20) | Continued PI (n = 19) | p Value | |
Men, no (%) | 15 (75%) | 15 (79%) | 1.0 |
Mean age, years (SD) | 46 (7.5) | 47 (12.5) | 0.80 |
Current smokers, n (%) | 9 (45%) | 7 (37%) | 0.61 |
Mean body mass index, kg/m2 (SD) | 23 (3.0) | 24 (2.3) | 0.37 |
Mean (SD) duration of HIV seropositivity, years | 10 (5.5) | 7.6 (4.7) | 0.14 |
Mean (SD) duration of antiretroviral therapy, years | 7.7 (3.7) | 5.7 (3.1) | 0.07 |
PI at time of randomisation* | 0.426 | ||
Lopinavir/ritonavir | 5 (25.0) | 3 (15.8) | |
Nelfinavir | 13 (65.0) | 16 (84.2) | |
Ritonavir, therapeutic dose | 1 (5.0) | 0 (0) | |
Indinavir/ritonavir | 1 (5.0) | 0 (0) | |
Clinical HIV CDC stage C, no (%) | 5 (25%) | 5 (26%) | 0.45 |
Mean (SD) systolic blood pressure, mm Hg | 125 (13) | 125 (17) | 0.96 |
Mean (SD) diastolic blood pressure, mm Hg | 77 (8.8) | 77 (9.0) | 0.91 |
Mean (SD) pulse, 1/min | 75 (7.4) | 74 (9.5) | 0.64 |
No (%) with HIV-1 RNA <50 copies/ml | 20 (100%) | 19 (100%) | 1.0 |
Mean (SD) CD4 cell count, cells/μl | 539 (250) | 520 (324) | 0.84 |
Mean (SD) total cholesterol, mmol/l | 6.5 (0.95) | 6.5 (1.1) | 0.78 |
Mean (SD) LDL, mmol/l | 4.0 (0.96) | 4.2 (0.9) | 0.52 |
Mean (SD) HDL, mmol/l | 1.2 (0.4) | 1.2 (0.3) | 0.85 |
Mean (SD) triglycerides, mmol/l | 3.2 (1.6) | 2.3 (1.0) | 0.04 |
Mean (SD) fasting glucose, mmol/l | 5.1 (0.6) | 5.0 (0.5) | 0.57 |
Mean (SD) insulin, mIU/l | 16.5 (18) | 10.5 (8.4) | 0.19 |
*The reverse transcriptase inhibitor backbone in the atazanavir and continued protease inhibitor (PI) groups, respectively, were statistically not different: zidovudine plus lamivudine, 14 and 13 patients; abacavir plus lamivudine, 0 and 4 patients; stavudine plus lamivudine, 2 and 1 patients; didanosine plus lamivudine, 1 and 1 patients; lamivudine plus tenovovir, 1 and 0 patients; zidovudine plus tenofovir, 1 and 0 patients; didanosine plus stavudine, 1 and 0 patients, respectively.
CDC, Centers for Disease Control and Prevention; HDL, high-density lipoprotein; LDL, low-density lipoprotein.